ArticlePLoS medicine2026
Overall and serotype-specific dengue virus transmission intensity in Mexico, 2016-2023: A modelling study of case-notification data.
Article in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Entomo-Molecular and Epidemiological Survey of Arboviruses inResearch and reports in tropical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMexico, and the Americas region more widely, have experienced increased dengue incidence in recent years, and there are concerns that the changing climate may enhance dengue virus (DENV) transmission in the future. Whilst previous studies have characterised spatial heterogeneities in the long-term average risk of DENV infection in Mexico, the extent to which DENV transmission changes year-to-year has not been investigated. Furthermore, the extent to which DENV's four serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) may differ in their transmissibility remains poorly characterised, both in Mexico and globally. METHODS AND
findingsIn this study, we characterised the spatial and temporal variations in DENV transmission intensity, as defined by the force of infection, across 27 states in Mexico. We analysed annual dengue case data reported to the National Epidemiological Surveillance System (SINAVE) in Mexico between 2016 and 2023, which comprised 833,629 probable or confirmed cases, using established catalytic models and a new, serotype-specific extension of these models that characterises differences in the transmission intensity of the different serotypes. We found evidence of large spatial, temporal, and serotype-specific heterogeneities in transmission intensity across Mexico. Serotype-specific force of infection estimates suggest that DENV-1 and DENV-2 have historically circulated at high levels across Mexico, with DENV-4 showing a low transmission intensity throughout the study period. We found evidence of increasing DENV-3 transmission intensity across some states in recent years, coinciding with large outbreaks. The extent to which the serotype-specific transmission intensity estimates generated in this study are affected by potential heterogeneities in case reporting across states and through time remains to be validated in future studies.
conclusionsThis work quantifies serotype-specific differences in DENV transmission intensity using routinely collected case-notification data and demonstrates how extensive RT-PCR testing and new rapid diagnostic tests capable of discerning infecting serotypes can help to better understand the contributions of different serotypes to DENV transmission. The methods developed in this study contribute to the development of a better understanding of the past and current burden of dengue infection, which can help to refine assessments of the potential impact of existing and new interventions in future analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.